Brian N Cherry
Insider
First SEC filing: Jan. 13, 2026 · Latest: Jan. 13, 2026
Insider at
Insider transactions
1 buys (P)
0 sells (S)
Net: $999,994
Avg return of open purchases vs now: -1.2%
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Sept. 4, 2026 | ATRA | P | 104,166 | $9.60 | $999,994 | 166,486 Direct | +167.15% | Acquired | -1.2% (price as of 2026-10-02) |
| June 11, 2026 | ATRA | A | 24,000 | · | · | 62,320 Direct | +62.63% | Acquired | (price as of 2026-10-02) |
| Jan. 12, 2026 | ZYME | A | 15,400 | · | · | 15,400 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 12, 2026 | ZYME | A | 23,000 | · | · | 23,000 Direct | · | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 12, 2026 | ZYME | Restricted Stock Unit | Common Stock | · | · | 15,400 | Acquired |
| Jan. 12, 2026 | ZYME | Stock Option (Right to Buy) | Common Stock | $23.16 | Jan. 11, 2036 | 23,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 3 holdings
Securities held when first becoming an insider, per SEC Form 3.